The same roundup notes Novo Nordisk plans to stop selling Saxenda in early 2027, and Zealand's petrelintide posted up to 9.2% weight loss in phase II.
Recap by typeshit. Full story at MedPage Today.
A local TV health segment on safety when using peptide therapy and GLP-1 drugs, aimed at men's health.
A Williamsburg shop sells injectable peptide vials for around $95 each, while the FDA has sent warning letters to sellers relying on the same label.
9:07
The endocrinologist takes on whether people can get retatrutide now, setting gray market supply against the results from Lilly's actual trials.
UW Medicine notes that many of these experimental peptides have not been regulated by the FDA, and some have never been tested in people.
A Medscape opinion roundup asks whether microdosing tirzepatide carries too much risk and whether surgery still matters, plus why sweet-and-salty snacks hook us.
King Khalid University researchers also report substantial weight regain after people stop the drug, and flag gallbladder and retinopathy signals worth watching.
Loading…